LEADER 01509nam  2200421z- 450 
001 9910689594903321
005 20161209101305.0
035   $a(CKB)4920000000787663
035   $a(BIP)008311345
035   $a(EXLCZ)994920000000787663
100   $a20220104c2002uuuu  -u-         -
101 0 $aeng
200 10$aCompetition in the pharmaceutical marketplace $eantitrust implications of patent settlements : hearing before the Committee on the Judiciary, United States Senate, One Hundred Seventh Congress, first session, May 24, 2001
215   $a1 online resource (iii, 49 p.) 
311   $a0-16-067057-8 
517   $aCompetition in the pharmaceutical marketplace 
606   $aPharmaceutical industry$zUnited States
606   $aCompetition$zUnited States
606   $aAntitrust law$zUnited States
606   $aPatent laws and legislation$zUnited States
606   $aWitnesses, FTC
610   $aPharmaceutical industry
610   $aCompetition
610   $aAntitrust law
610   $aPatent laws and legislation
610   $aWitnesses
610   $aBusiness & economics
610   $aLaw
615  0$aPharmaceutical industry
615  0$aCompetition
615  0$aAntitrust law
615  0$aPatent laws and legislation
615  4$aWitnesses, FTC.
712 02$aUnited States, Congress Senate Committee on the Judiciary Staff,$4oth
906   $aBOOK
912   $a9910689594903321
996   $aCompetition in the pharmaceutical marketplace$93142575
997   $aUNINA